Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1][2]. Company Overview: Cemex (CX) - Cemex currently holds a Momentum Style Score of B, indicating a positive momentum outlook [3]. - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4]. Performance Metrics - Over the past week, Cemex shares have increased by 8.44%, while the Zacks Building Products - Concrete and Aggregates industry has declined by 1.21% [6]. - In the last month, Cemex's stock price has risen by 10.67%, significantly outperforming the industry's 0.3% increase [6]. - Over the past three months, shares have appreciated by 18.18%, and over the last year, they have surged by 78.61%, compared to the S&P 500's gains of 8.21% and 18.84%, respectively [7]. Trading Volume - The average 20-day trading volume for Cemex is 11,152,314 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, one earnings estimate for Cemex has increased, while none have decreased, leading to a consensus estimate rise from $0.75 to $0.92 [10]. - For the next fiscal year, one estimate has also moved upwards, with no downward revisions noted [10]. Conclusion - Given the positive momentum indicators and earnings outlook, Cemex is positioned as a strong buy candidate for investors seeking short-term gains [11][12].

Core Insights - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] - Relay Therapeutics, Inc. (RLAY) currently holds a Momentum Style Score of B, indicating a favorable position in momentum investing [3][12] - The Zacks Rank for Relay Therapeutics is 2 (Buy), suggesting strong potential for outperformance in the market [4][12] Price Performance - RLAY shares have increased by 5.7% over the past week, while the Zacks Medical - Drugs industry remained flat during the same period [6] - Over the last month, RLAY's price change is 42.2%, significantly outperforming the industry's 0.47% [6] - In the past quarter, RLAY shares have risen by 102.19%, and they are up 22.39% over the last year, compared to the S&P 500's increases of 7.9% and 19.67%, respectively [7] Trading Volume - RLAY's average 20-day trading volume is 1,878,524 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, one earnings estimate for RLAY has increased, while none have decreased, leading to a consensus estimate improvement from -$1.62 to -$1.59 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings momentum [10]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: HF Sinclair (DINO) - HF Sinclair currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 1 (Strong Buy), suggesting it is expected to outperform the market [3] Price Performance - Over the past week, DINO shares increased by 5.17%, while the Zacks Oil and Gas - Refining and Marketing industry rose by 6.12% [5] - In the last quarter, DINO shares have risen by 25.03%, and over the past year, they are up 27.66%, significantly outperforming the S&P 500, which increased by 7.9% and 19.67% respectively [6] Trading Volume - DINO's average 20-day trading volume is 1,688,161 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, 5 earnings estimates for DINO have been revised upwards, increasing the consensus estimate from $2.80 to $4.41 [9] - For the next fiscal year, 5 estimates have moved higher, while 1 has been revised downwards [9] Conclusion - Given the strong momentum indicators and positive earnings outlook, DINO is positioned as a 1 (Strong Buy) stock with a Momentum Score of A, making it a compelling investment option [11]

Core Viewpoint - Vodafone Group PLC (VOD) is identified as a promising momentum stock, currently holding a Momentum Style Score of B and a Zacks Rank of 2 (Buy) [3][4][12] Price Performance - VOD shares have increased by 3.27% over the past week, outperforming the Zacks Wireless Non-US industry, which rose by 2.79% during the same period [6] - Over the last month, VOD's price change is 3.46%, compared to the industry's 2.21% [6] - In the last quarter, VOD shares rose by 7.86%, and over the past year, they increased by 22.61%, while the S&P 500 only moved 6.22% and 17.55%, respectively [7] Trading Volume - VOD's average 20-day trading volume is 4,801,757 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Estimates - In the past two months, one earnings estimate for VOD has increased, while none have decreased, raising the consensus estimate from $1.04 to $1.05 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions [10] Conclusion - Given the positive price trends and earnings outlook, VOD is positioned as a strong candidate for investors seeking momentum stocks [12]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Amylyx Pharmaceuticals, Inc. (AMLX) - AMLX currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Performance Metrics - Over the past week, AMLX shares increased by 4.84%, while the Zacks Medical - Drugs industry remained flat [6] - In the last quarter, AMLX shares rose by 78.21%, and over the past year, they increased by 192.04%, significantly outperforming the S&P 500, which rose by 6.22% and 17.55% respectively [7] - The average 20-day trading volume for AMLX is 2,035,068 shares, indicating strong trading activity [8] Earnings Outlook - In the past two months, two earnings estimates for AMLX have been revised upwards, with the consensus estimate improving from -$1.71 to -$1.58 [10] - For the next fiscal year, two estimates have also moved upwards, with no downward revisions during the same period [10] Conclusion - Given the strong performance metrics and positive earnings outlook, AMLX is identified as a promising momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1]. Company Overview: Helios Technologies (HLIO) - Helios Technologies currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating strong potential for outperformance in the market [2][3]. - The company specializes in manufacturing screw-in hydraulic cartridge valves and manifolds, positioning it as a promising momentum pick [3]. Price Performance - HLIO shares have increased by 12.46% over the past week, significantly outperforming the Zacks Manufacturing - General Industrial industry, which rose by 1.74% during the same period [5]. - Over the past quarter, HLIO shares have surged by 47.83%, and they have gained 17.51% over the last year, compared to the S&P 500's increases of 7.07% and 16.3%, respectively [6]. Trading Volume - The average 20-day trading volume for HLIO is 277,821 shares, which serves as a bullish indicator when combined with rising stock prices [7]. Earnings Outlook - In the last two months, one earnings estimate for HLIO has been revised upward, while none have been lowered, resulting in an increase in the consensus estimate from $2.40 to $2.41 [9]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions, indicating positive earnings momentum [9]. Conclusion - Given the strong price performance, positive earnings outlook, and solid momentum score, HLIO is positioned as a compelling buy for investors seeking short-term gains [11].

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher as stocks tend to continue in their established direction [1] - TJX currently holds a Momentum Style Score of A, indicating strong momentum characteristics, supported by price changes and earnings estimate revisions [2][3] Company Performance - TJX shares have increased by 2.46% over the past week, while the Zacks Retail - Discount Stores industry has risen by 6.21% during the same period [5] - Over the last quarter, TJX shares have gained 13.76%, and over the past year, they have increased by 22.2%, outperforming the S&P 500, which moved 6.14% and 15.41% respectively [6] - The average 20-day trading volume for TJX is 4,638,315 shares, indicating a bullish sentiment when combined with rising stock prices [7] Earnings Outlook - In the past two months, 7 earnings estimates for TJX have been revised upwards, increasing the consensus estimate from $4.48 to $4.64 [9] - For the next fiscal year, 6 estimates have also moved higher, with no downward revisions noted [9] Conclusion - Given the strong performance metrics and positive earnings outlook, TJX is rated as a 2 (Buy) stock with a Momentum Score of A, making it a promising investment opportunity [10]

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - The Zacks Momentum Style Score helps investors identify stocks with strong momentum, addressing the challenges of defining momentum [2] Company Overview: Verastem (VSTM) - Verastem currently holds a Momentum Style Score of A, indicating strong momentum potential [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Performance Metrics - Over the past week, VSTM shares increased by 7.58%, while the Zacks Medical - Biomedical and Genetics industry remained flat [6] - In the last quarter, VSTM shares rose by 50.16%, and over the past year, they gained 211.49%, significantly outperforming the S&P 500, which increased by 6.14% and 15.41% respectively [7] Trading Volume - VSTM's average 20-day trading volume is 1,758,705 shares, indicating a bullish sign as rising stocks with above-average volume are generally viewed positively [8] Earnings Outlook - In the past two months, one earnings estimate for VSTM has increased, while none have decreased, leading to a consensus estimate improvement from -$3.11 to -$2.44 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings momentum [10] Conclusion - Considering the strong performance metrics and positive earnings outlook, VSTM is recommended as a 2 (Buy) stock with a Momentum Score of A, making it a compelling option for investors seeking short-term gains [12]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Zymeworks Inc. (ZYME) - Zymeworks Inc. currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Price Performance - ZYME shares have increased by 6.61% over the past week, while the Zacks Medical - Biomedical and Genetics industry has decreased by 0.34% during the same period [6] - Over the past month, ZYME's price has risen by 13.69%, outperforming the industry's 6.95% [6] - In the last quarter, ZYME shares rose by 26.47%, and over the past year, they increased by 36.17%, compared to the S&P 500's gains of 6.67% and 15.74%, respectively [7] Trading Volume - ZYME's average 20-day trading volume is 678,382 shares, which serves as a baseline for price-to-volume analysis [8] Earnings Outlook - In the past two months, three earnings estimates for ZYME have been revised upward, while none have been revised downward, improving the consensus estimate from -$0.99 to -$0.75 [10] - For the next fiscal year, three estimates have moved up, with one downward revision noted [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, Zymeworks Inc. is positioned as a promising investment opportunity [12]

Core Insights - MKS Instruments, Inc. is a leading global provider of instruments and process control solutions for advanced manufacturing across various industries, including semiconductor and life sciences [1] - The company competes with major players like Applied Materials and Lam Research in the semiconductor equipment sector [1] Stock Performance - On October 13, 2025, Morgan Stanley upgraded MKSI to "Overweight" with a price target increase from $120 to $151, indicating a positive outlook [2] - At the time of the upgrade, MKSI was trading at approximately $130.18, with a recommendation to hold [2] - MKSI has shown a price increase of 13.18% over the past week, attracting momentum investors [3] - The current stock price is $133.01, reflecting an increase of 9.69% or $11.75 [4] - The stock has fluctuated between a low of $127.77 and a high of $133.18 during the trading day [4] - Over the past year, MKSI has reached a high of $142.20 and a low of $54.84 [4] - The market capitalization of MKS Instruments is approximately $8.93 billion, with a trading volume of 397,954 shares on NASDAQ [4]